Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03716726 · ClinicalTrials.gov registry record · NA
Sickle Cell Anemia WE CARE
A NA study of Sickle Cell Disease, sponsored by Boston Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT03716726: Completed NA study of Sickle Cell Disease, sponsored by Boston Medical Center.
NCT03716726 is a NA study of Sickle Cell Disease that has completed, run by Boston Medical Center. The registered enrollment target is 112 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03716726, a NA study of Sickle Cell Disease, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
This mixed-methods study aims to understand the implementation of a previously tested, efficacious social determinants of health (SDoH) screening and referral intervention in the outpatient pediatric hematology setting; qualitatively assess possible mechanisms for such interventions on improving child health; and obtain population-specific empirical estimates to plan a large-scale clinical trial.
Primary Outcome
Data on number of ED visits and acute care visits abstracted from the EHR.
Conditions Studied
Interventions
- OTHER Standard of care
- BEHAVIORAL WE CARE SDoH Screening Survey
- BEHAVIORAL Family Resource Book
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-01-21 |
| Est. Completion | 2023-02-01 |
| Phase | NA |
What the finished NCT03716726 record still lists
NCT03716726 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Standard of care is the first listed.
NCT03716726 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03716726 about?
NCT03716726 is a clinical study titled "Sickle Cell Anemia WE CARE". This mixed-methods study aims to understand the implementation of a previously tested, efficacious social determinants of health (SDoH) screening and referral intervention in the outpatient pediatric hematology setting; qualitatively assess possible mechanisms for such interventions on improving chi...
What is the current status of trial NCT03716726?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2021-01-21. Estimated completion is 2023-02-01.
What conditions does trial NCT03716726 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT03716726?
The interventions under investigation include: Standard of care (OTHER), WE CARE SDoH Screening Survey (BEHAVIORAL), Family Resource Book (BEHAVIORAL).
Who is sponsoring clinical trial NCT03716726?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03716726 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03716726's enrollment target sits among peer trials
112 56th of 213 higher than 158 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI